Fenretinide is under clinical development by Laurent Pharmaceuticals and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fenretinide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fenretinide overview
Fenretinide (LAU-7b) is under development for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), long covid and cystic fibrosis patients chronically infected with Pseudomonas aeruginosa. It is administered through oral route in the form of capsule. The drug candidate is an improved solid oral dosage form of fenretinide which acts by targeting elevated levels of arachidonic acid and docosahexaenoic acid (AA/DHA).
Laurent Pharmaceuticals overview
Laurent Pharmaceuticals (Laurent) is a clinical-stage biotech company that focuses on modulating cell membrane lipids for life-threatening disease treatment. The company’s lead drug LAU-7b, is an oral drug candidate based on fenretinide, an atypical retinoid (vitamin A derivative) that targets COVID-19 and cystic fibrosis diseases. Its LAU-7b shows the potential to regulate membrane lipids and exert antiviral, inflammation-controlling and antifibrotic properties. Laurent is headquartered in Montreal, Quebec, Canada.
For a complete picture of Fenretinide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
